PTSD can improve with treatment, and trauma-focused psychotherapy is a leading clinical option. The eligible nonprofit-funded trial reviewed here supports cognitive therapy, while guideline recommendations cover a broader evidence base. Some large public-funded trials have author commercial interests and are shown as comparative context. Confidence: moderate for reviewed cognitive-therapy benefit; low for supplements. There is no universal best treatment or established supplement cure (Ehlers 2014 cognitive-therapy trial; VA: psychotherapy guidance).
- PTSD is a diagnosable condition after trauma, not a failure of resilience (NIMH: PTSD).
- VA/DoD recommends prolonged exposure, cognitive processing therapy and EMDR; treatment choice is shared (VA: psychotherapy guidance).
- Public funding does not erase manual royalties or author treatment interests (Schnurr 2022 comparative trial; Sloan 2023 written-exposure trial).
- Supplements cannot be recommended as replacements from this review; safety and ongoing threat need attention.
Table of contents
- Evidence summary
- What it is
- How it works
- The evidence-based treatments
- Supplement and lifestyle evidence
- What works and what does not
- Risks and side effects
- Important interactions
- Who should avoid
- Prescribing information and how to use treatment
- Animal and in-vitro evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Benefit, recommendation strength and independence are separate judgments. A trial comparing two therapies cannot alone show how either compares with receiving no treatment.
| Claim | Evidence reviewed | Source | Funding / conflict | Interpretation / limits |
|---|---|---|---|---|
| Cognitive therapy | 121 adults: intensive and weekly therapy versus supportive therapy and waitlist. Recovery proportions at 14 weeks: 73%, 77%, 43%, 7%. | Ehlers 2014 cognitive-therapy trial | Wellcome; no reported commercial relationships. | Small groups; developers involved; not a universal recovery forecast. |
| Leading therapies | VA/DoD favors PE, CPT and EMDR over medication. | VA: psychotherapy guidance | Public institution; underlying trials have separate ties. | Clinical synthesis, not independent replication. |
| PE versus CPT | 916 veterans; small PE advantage below predefined clinical significance; dropout 55.8% versus 46.6%. | Schnurr 2022 comparative trial | VA; royalties, fees and author pharma relationships. | Interested comparative context; not strict independent efficacy basis. |
| Written exposure | 178 veterans; noninferior to PE within prespecified margin. | Sloan 2023 written-exposure trial | VA grant; manual royalties and training fees. | Context; shorter care is not automatically suitable for everyone. |
| Medicines | 2023 guidance supports sertraline, paroxetine and venlafaxine; prazosin distinction is nightmare-specific. | VA: medication guidance | Public guidance; drug-trial finances not fully cleared. | Recommendations require individualized prescribing. |
| DHA/omega-3 | 110 injured adults; no advantage over placebo for the studied prevention endpoint. | Matsuoka 2015 DHA prevention trial | Public grant; Kentech supply and author industry ties. | Excluded from independent efficacy basis; prevention is not established-PTSD treatment. |
What PTSD is
PTSD can follow qualifying trauma, including violence, serious accidents or disasters. Symptoms include intrusive memories or nightmares, avoidance, heightened alertness, and negative mood or beliefs. They must persist beyond one month, impair life, and not be better explained by substances or another illness. Not everyone exposed to trauma develops PTSD, and assessment should cover depression, dissociation, substance use and suicide risk (NIMH: PTSD).
How it works
Trauma memories, threat interpretations and avoidance can maintain symptoms. Cognitive therapy addresses unhelpful meanings and patterns; exposure-based approaches help patients encounter memories and safe reminders within structured care. These clinical models do not establish a single cause or prove that any supplement can “reset” stress biology (Ehlers 2014 cognitive-therapy trial; VA: psychotherapy guidance).
The evidence-based treatments
A trained trauma therapist can discuss PE, CPT, EMDR and other structured options. The 2023 VA/DoD guideline favors specified trauma-focused psychotherapies; NICE also recommends trauma-focused CBT and offers EMDR under specified adult circumstances. Preferences, access, readiness and other conditions matter. Guidelines draw on mixed provenance evidence, so their recommendations are reported without relabeling every supporting trial independent (VA: psychotherapy guidance; NICE NG116).
Medication is an option when preferred or when psychotherapy is unavailable or unsuitable. VA guidance supports sertraline, paroxetine and venlafaxine. Prazosin is suggested for PTSD-associated nightmares, while guidance suggests against using it for PTSD overall. Local approvals and prescribing decisions differ (VA: medication guidance).
Supplement and lifestyle evidence
Regular meals, sleep routines, supportive relationships and suitable activity can support recovery; they do not replace trauma treatment. The reviewed DHA study tested prevention after injury, not established PTSD, and had commercial product support. This review does not establish omega-3, magnesium, probiotics, melatonin or herbal mixtures as PTSD treatments. Correcting a confirmed deficiency answers a separate medical question (NIMH: PTSD; Matsuoka 2015 DHA prevention trial).
What works and what does not
The eligible cognitive-therapy trial supports benefit within its studied population. Guideline-recommended care has broader clinical support, with sponsorship caveats. NICE advises against psychologically focused debriefing to prevent or treat PTSD. Pressuring someone to recount trauma immediately is different from a planned therapeutic intervention. No symptom improvement claim should promise permanent cure (Ehlers 2014 cognitive-therapy trial; NICE NG116).
Risks and side effects
Trauma-focused work can be emotionally demanding; clinician support matters. Seek immediate local emergency help for suicidal intent, danger from violence, inability to stay safe or a severe reaction. Ongoing trauma needs practical safety support alongside treatment. Symptoms after trauma do not require waiting a month before seeking help (NIMH: PTSD).
Important interactions
Have a pharmacist review all medicines, alcohol, recreational drugs and supplements. Prescribing requires assessment of other psychiatric conditions and adverse effects. VA/DoD recommends against benzodiazepines and cannabis or cannabis derivatives for PTSD. Starting, combining or stopping psychiatric medicines requires clinician supervision (VA: medication guidance).
Who should avoid
Avoid self-directed exposure exercises when safety is unstable or severe symptoms need clinical support. Pregnancy, children, bipolar symptoms, substance dependence and multiple medicines need tailored care. A substance-use problem is not by itself a reason to deny PTSD treatment; NICE recommends addressing barriers and complex needs (NICE NG116).
Prescribing information and how to use treatment
No personalized dose or self-treatment protocol is supplied. Agree goals, measure symptoms and daily function, monitor adverse effects, and plan follow-up. Trial schedules are descriptions of research. A five-session written-exposure trial does not validate unguided trauma journaling or make it interchangeable with treatment by a trained therapist (Sloan 2023 written-exposure trial).
Animal and in-vitro evidence
Animal and cell studies are excluded from the human benefit verdict. Changes in fear circuitry, inflammation or neurogenesis do not demonstrate PTSD remission or safe long-term human treatment.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 5 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Clinics, therapists, drug and supplement sellers, app companies and training/manual publishers may earn revenue from PTSD care. The diagram and scorecard distinguish public grants, nonprofit capital, product support and author income. No undisclosed control is inferred. Evidence is concentrated in the United States and United Kingdom, with one Japanese prevention trial; civilian, cultural and trauma differences limit transfer.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NIMH: PTSD | US federal NIH/HHS funding; budget disclosure. | United States; federal agency | Tier 1 — institutional education | A — Public accountability and clinical accuracy. Educational synthesis, not trial-level conflict clearance. |
| NICE NG116 | Public grants plus fee/research income; 2025–26 accounts. | United Kingdom; public body, London | Tier 2 — indirect institutional ties | B — Transparent national recommendations. Budget/implementation priorities; underlying trial finances not all independently audited. |
| VA: psychotherapy guidance | US VA/DoD public institutions; provider and implementation interests. | United States; federal programs | Tier 1 institutional; synthesis not fully cleared | A (provisional) — Clinical accountability and documented recommendations. Treatment-program allegiance; cited trials retain their own conflicts. |
| VA: medication guidance | US VA/DoD public institutions; source summarizes 2023 guideline. | United States; federal programs | Tier 1 institutional; synthesis not fully cleared | A (provisional) — Clinical accountability and explicit recommendation grading. Underlying drug-trial sponsorship not exhaustively traced. |
| Ehlers 2014 cognitive-therapy trial | Wellcome grant 069777; no commercial relationships reported. Investment returns fund the foundation; therapy-development allegiance remains. | United Kingdom; London trial/foundation | Tier 2 — indirect/allegiance caveat | B — Randomized active comparator and independent outcome assessors. Therapy developers involved; investment interests not fully mapped; one 121-person trial. |
| Schnurr 2022 comparative trial | VA Cooperative Studies Program. Author therapy-manual royalties/training fees and other pharma relationships disclosed. | United States; 17 VA centers | Tier 3 — interested authors | C — Large registered trial with masked assessors. VA involved throughout; therapy commercialization and high dropout. |
| Sloan 2023 written-exposure trial | VA CX001967; Sloan/Marx therapy-manual royalties, Marx PESI fees. | United States; VA trial | Tier 3 — interested authors | C — Randomized noninferiority design and masked assessors. Manual income; noninferiority is not identical benefit for every patient. |
| Matsuoka 2015 DHA prevention trial | Japan Science and Technology Agency CREST; Kentech supplied supplements. Author DHA-industry and pharma fees/support disclosed. | Japan; Tokyo trial, Toyama supplier | Tier 4 — commercial product support | D for independent efficacy; methods assessed separately — Published randomized placebo comparison. Commercial supply and author ties; prevention after injury differs from treating established PTSD. |
Frequently asked questions
Is PTSD only a military condition?
No. Civilians of any age can develop it after qualifying trauma (NIMH: PTSD).
Must I discuss every detail immediately?
No. Treatment should use consent, a planned method and safety support. Compulsory early debriefing is not recommended (NICE NG116).
Why disclose public-funded trial royalties?
Grant sponsorship and personal financial incentives are separate. Manual income does not prove false results, but prevents an unqualified claim of independence (Schnurr 2022 comparative trial; Sloan 2023 written-exposure trial).
Sources and funding notes
Original trial methods, results and financial disclosures were checked. Guidance describes professional recommendations; it does not certify every underlying trial as independent. The scorecard gives the source-specific funding and limitations. This is a focused evidence review, not an exhaustive systematic review.
- NIMH: PTSD
- NICE NG116
- VA: psychotherapy guidance
- VA: medication guidance
- Ehlers 2014 cognitive-therapy trial
- Schnurr 2022 comparative trial
- Sloan 2023 written-exposure trial
- Matsuoka 2015 DHA prevention trial
- Wellcome funding disclosure
- NICE 2025–26 accounts
- NIMH budget disclosure
Last reviewed: October 4, 2026. Educational information; diagnosis, treatment selection and monitoring require a qualified clinician.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.